Alto Neuroscience (ANRO) Short term Debt (2024 - 2026)

Alto Neuroscience (ANRO) posted Short term Debt of $2.1 million for Q1 2026, up 265.13% sequentially from $585000.0 in Q4 2025.

Alto Neuroscience (ANRO) Short term Debt (2024 - 2026) Analysis & Trends

Alto Neuroscience has reported Short term Debt for 3 years, with the latest figure at $2.1 million in Q1 2026.

Quarterly Short term Debt changed N/A year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (changed N/A YoY) and the FY2025 annual result came in at $585000.0, changed N/A from the prior year.
Short term Debt grew to $2.1 million in Q1 2026 per ANRO's latest filing, from $585000.0 in the prior quarter.
Over five years, Short term Debt peaked at $3.5 million in Q3 2024 and troughed at $585000.0 in Q4 2025.
A 3-year average of $1.9 million and a median of $2.1 million in 2026 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Alto Neuroscience	1.13 Bn	1.13 Bn	-

Download Data